Citations 63

Advance in Iron Metabolism, Oxidative Stress and Cellular Dysfunction in Experimental and Human Kidney Diseases

Antioxidants | May 28, 2024 | Volume: 13 | Issue: 6 | Pages: 659

10.3390/antiox13060659 | PMID 38929098

Kidney diseases pose a significant global health issue, frequently resulting in the gradual decline of renal function and eventually leading to end-stage renal failure. Abnormal iron metabolism and oxidative stress-mediated cellular dysfunction facilitates the advancement of kidney diseases. Iron homeostasis is strictly regulated in the body, and disturbance in this regulatory system results in abnormal iron accumulation or deficiency, both of which are associated with the pathogenesis of kidney diseases. Iron overload promotes the production of reactive oxygen species (ROS) through the Fenton reaction, resulting in oxidative damage to cellular molecules and impaired cellular function. Increased oxidative stress can also influence iron metabolism through upregulation of iron regulatory proteins and altering the expression and activity of key iron transport and storage proteins. This creates a harmful cycle in which abnormal iron metabolism and oxidative stress perpetuate each other, ultimately contributing to the advancement of kidney diseases. The crosstalk of iron metabolism and oxidative stress involves multiple signaling pathways, such as hypoxia-inducible factor (HIF) and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways. This review delves into the functions and mechanisms of iron metabolism and oxidative stress, along with the intricate relationship between these two factors in the context of kidney diseases. Understanding the underlying mechanisms should help to identify potential therapeutic targets and develop novel and effective therapeutic strategies to combat the burden of kidney diseases.
Epigenetic Age Is Accelerated in ADPKD Kidneys and Is Regulated by Autophagy-Mediated DNA Methyltransferase

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 561-562

10.1681/asn.20233411s1561e

Pkd1 Mutation Causes Memory Impairment Driving by Cellular Senescence in ADPKD

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 560-560

10.1681/asn.20233411s1560a

The Immune Checkpoint Protein PD-L1 Interacts with BBS5 to Regulate Ciliogenesis and Hedgehog Signaling

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 563-563

10.1681/asn.20233411s1563c

Progressive Cellular Senescence Promotes and Senolytic Therapy Delays Cyst Growth in ADPKD

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 558-558

10.1681/asn.20233411s1558b

Identification and Characterization of Biomarkers from Cell-Free DNA Methylation in ADPKD Patients

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 210-210

10.1681/asn.20233411s1210b

Targeting ALDH1A1 with Nanoparticle-Based Immunotherapy on Kidney PD-L1 Synergistically Delays Cyst Growth

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 205-205

10.1681/asn.20233411s1205c

Therapeutic Blocking of IL-17A Binding to IL-17RA Diminishes PD-L1 Expression Is a Novel Therapeutic Approach for ADPKD

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 205-205

10.1681/asn.20233411s1205b

Establishment and Application a Novel Reversible Unilateral Ureteral Obstruction (RUUO) Mouse Model and in Mechanism Study of AKI to CKD

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 34 | Issue: 11S | Pages: 704-704

10.1681/asn.20233411s1704b

SMYD3 Regulates Cyst Growth and Ciliogenesis in Autosomal Dominant Polycystic Kidney Disease

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 398-398

10.1681/asn.20223311s1398c